Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment
| Autor: | SJ Warrington, Atholl Johnston, JA Henry, NA Hamer |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Pyridines Urology Renal function Pharmacokinetics Oral administration Internal medicine medicine Humans Pharmacology (medical) Aged Pharmacology Volume of distribution business.industry Half-life Middle Aged Regimen Endocrinology Kidney Failure Chronic Female Disopyramide Phosphate Disopyramide business Research Article Half-Life medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 10:245-248 |
| ISSN: | 0306-5251 |
| DOI: | 10.1111/j.1365-2125.1980.tb01751.x |
| Popis: | 1 The pharmacokinetics of disopyramide were studied after the oral administration of a 300 mg dose to 11 patients with stable chronic renal impairment (creatinine clearance 2-53 ml min-1). 2 Absorption half-life and volume of distribution were similar to those seen in normal subjects. 3 Mean plasma elimination half-life in these patients was 12.7 h, which is substantially greater than that reported for normal subjects. Elimination half-life tended to increase as creatinine clearance fell, and renal clearance of disopyramide correlated significantly (r=0.814; P < 0.001) with creatinine clearance. 4 From these results, we have calculated that patients with renal impairment should be started on a dose of disopyramide 1.5 mg kg-1 thrice daily and the regimen subsequently altered according to plasma concentrations of the drug. However, further studies are needed to define the handling of the metabolites of disopyramide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text